Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Eric Tsobanis"'
Autor:
Katrin M. Sjoquist, Andrew Martin, Nick Pavlakis, David Goldstein, Eric Tsobanis, Daniel Moses, Richard Maher, Wendy Hague, Val Gebski, Martin R. Stockler, R. John Simes
Publikováno v:
Journal of cancer research and clinical oncology.
Purpose Activity estimates should be accurately evaluated in phase 2 clinical trials to ensure appropriate decisions about proceeding to phase 3 trials. RECIST v1.1. progression-free survival (PFS) is a common endpoint in oncology; however, it can be
Autor:
Eric Tsobanis, John Zalcberg, Nick Pavlakis, Sun Young Rha, Andrew J. Martin, Margot J. Burnell, Mark Wong, Andrew Strickland, Christopher J. O'Callaghan, Sonia Yip, Jeeyun Lee, Jin Won Kim, John Simes, Yoon-Koo Kang, Jae Yong Cho, Yung-Jue Bang, Thierry Alcindor, Katrin Marie Sjoquist, David Goldstein, Niall C. Tebbutt, Lara Lipton
Publikováno v:
Journal of Clinical Oncology. 34:2728-2735
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in
Autor:
Katrin Marie Sjoquist, Eric Tsobanis, Axel Grothey, Yu Jo Chua, Hiroki Hara, Li-Tzong Chen, Taito Esaki, David Goldstein, Sonia Yip, John Simes, John Zalcberg, Nick Pavlakis, Tanios Bekaii-Saab, Andrew J. Martin, Yoshito Komatsu, Nozomu Machida, Thierry Alcindor, Yung-Jue Bang, Christopher J. O'Callaghan, Kohei Shitara
Publikováno v:
Annals of Oncology. 30:vi137
Background AGOC has a poor prognosis with limited benefits from treatments following failure of chemotherapy (CT). Regorafenib (BAY 73-4506)(REG) is an oral multi-kinase inhibitor targeting kinases involved in angiogenesis (VEGFR1-3, TIE-2), tumor mi
Autor:
Sarah A. Hayes, Andrew Martin, Sonia Yip, Viive M. Howell, Katrin M. Sjoquist, Eric Tsobanis, Yoon-Koo Kang, Yung-Jue Bang, Thierry Alcindor, Christopher J. O'Callaghan, Niall C. Tebbutt, John Simes, David Goldstein, Nick Pavlakis
Publikováno v:
Cancer Research. 79:4531-4531
Introduction: Gastric cancer is one of the most common cancers worldwide, and a leading cause of cancer death. Advanced OesophagoGastric cancer (AOGC) has a poor prognosis despite treatment. The P2 INTEGRATE multinational 2:1 (active:placebo) randomi
Autor:
Li-Tzong Chen, Christopher J. O'Callaghan, David Goldstein, Eric Tsobanis, Kohei Shitara, John Zalcberg, Thierry Alcindor, Katrin Marie Sjoquist, Axel Grothey, Sonia Yip, Nick Pavlakis, Yung-Jue Bang, Andrew J. Martin, Tanios Bekaii-Saab, John Simes
Publikováno v:
Journal of Clinical Oncology. 35:TPS4136-TPS4136
TPS4136 Background: AGOC has a poor prognosis with no established standard treatment following failure of chemotherapy (CT). Regorafenib (BAY 73-4506)(REG) is an oral multi-kinase inhibitor targeting kinases involved in angiogenesis (VEGFR1-3, TIE-2)
Autor:
Andrew J. Martin, Eric Tsobanis, John Simes, David Goldstein, Jae Yong Cho, Yung-Jue Bang, Andrew Strickland, John Zalcberg, Sun Young Rha, Margot J. Burnell, Jeeyun Lee, Nick Pavlakis, Sonia Yip, Niall C. Tebbutt, Rozelle Harvie, Thierry Alcindor, Lara Lipton, Christopher J. O'Callaghan, Katrin Marie Sjoquist, Yoon-Koo Kang
Publikováno v:
Journal of Clinical Oncology. 34:64-64
64 Background: The INTEGRATE study evaluated activity of regorafinib (REG) v placebo (PBO) in 147 eligible patients with refractory AOGC. REG was highly effective in prolonging progression free survival (PFS). Differences between regions (i.e. Austra
Autor:
Sun Young Rha, Eric Tsobanis, David Goldstein, J.W. Lee, Christopher J. O'Callaghan, Nick Pavlakis, Katrin Marie Sjoquist, Lara Lipton, J.W. Kim, Niall C. Tebbutt, John Zalcberg, Y-K. Kang, Andrew J. Martin, Jin Young Cho, Andrew Strickland, Margot J. Burnell, Sonia Yip, John Simes, Y.-J. Bang, Thierry Alcindor
Publikováno v:
Annals of Oncology. 26:iv119
Autor:
Christopher J. O'Callaghan, Nick Pavlakis, Yoon-Koo Kang, Eric Tsobanis, Andrew J. Martin, Thierry Alcindor, Lara Lipton, Jae Yong Cho, Margot J. Burnell, Katrin Marie Sjoquist, Andrew Strickland, Niall C. Tebbutt, David Goldstein, Jin Won Kim, Yung-Jue Bang, Sun Young Rha, Sonia Yip, John Simes, Jeeyun Lee, John Zalcberg
Publikováno v:
Journal of Clinical Oncology. 33:4003-4003
4003 Background: REG is an oral multi-kinase inhibitor warranting evaluation in AOGC following failure of 1st or 2nd line chemotherapy (CT) where few options exist. Methods: International (Australia & New Zealand (ANZ), Korea, Canada (NCIC CTG)) phas
Autor:
Andrew J. Martin, Niall C. Tebbutt, Katrin Marie Sjoquist, Eric Tsobanis, Margot J. Burnell, John Simes, John Zalcberg, Jae Yong Cho, Jeeyun Lee, Sun Young Rha, Christopher J. O'Callaghan, Thierry Alcindor, Yung-Jue Bang, Mark Wong, Yoon-Koo Kang, Lara Lipton, Jin Won Kim, David Goldstein, Nick Pavlakis, Andrew Strickland
Publikováno v:
Journal of Clinical Oncology. 33:9-9
9 Background: Advanced Oesophago-Gastric Carcinoma (AOGC) has limited options following failure of first or second line chemotherapy (CT). Regorafenib (REG) is an oral multi-kinase inhibitor of kinases involved in angiogenesis, tumor microenvironment
Autor:
Nadine M Magoski, Eric Tsobanis, Yvonne Murray, Jeremy Shapiro, Nicole Mittmann, Louise M. Nott, Christopher J. O'Callaghan, Michael M. Vickers, Derek J. Jonker, John Simes, Atsushi Ohtsu, Alice Chia-chi Wei, Chiang Li, David Kerstein, Takayuki Yoshino, Sharlene Gill, John Zalcberg, Dongsheng Tu
Publikováno v:
Journal of Clinical Oncology. 32:TPS3660-TPS3660
TPS3660 Background: BBI608 is an orally-administered first-in-class cancer stemness inhibitor which blocks cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem can...